In prostate cancer, comparison of gene expression profiles between newly-diagnosed, androgen-dependent and androgen-independent primary tumours from patients with metastatic disease [59], revealed higher MRPL20 expression in androgen-independent samples, suggesting a possible role in aggressive prostate cancer [59]. This evidence concerns the gene MRPL20 and prostate carcinoma.